SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy